BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

112 related articles for article (PubMed ID: 10706935)

  • 1. Epitope mapping of monoclonal antibodies directed to PAI-1 using PAI-1/PAI-2 chimera and PAI-1-derived synthetic peptides.
    Muehlenweg B; Guthaus E; de Prada NA; Schmitt M; Schmiedeberg N; Kotzsch M; Creutzburg S; Kramer MD; Kessler H; Wilhelm OG; Magdolen V
    Thromb Res; 2000 Apr; 98(1):73-81. PubMed ID: 10706935
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Epitope mapping for four monoclonal antibodies against human plasminogen activator inhibitor type-1: implications for antibody-mediated PAI-1-neutralization and vitronectin-binding.
    Wind T; Jensen MA; Andreasen PA
    Eur J Biochem; 2001 Feb; 268(4):1095-106. PubMed ID: 11179976
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Elucidation of the binding regions of PAI-1 neutralizing antibodies using chimeric variants of human and rat PAI-1.
    Bijnens AP; Ngo TH; Gils A; Dewaele J; Knockaert I; Stassen JM; Declerck PJ
    Thromb Haemost; 2001 May; 85(5):866-74. PubMed ID: 11372681
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Additivity in effects of vitronectin and monoclonal antibodies against alpha-helix F of plasminogen activator inhibitor-1 on its reactions with target proteinases.
    Komissarov AA; Andreasen PA; Bødker JS; Declerck PJ; Anagli JY; Shore JD
    J Biol Chem; 2005 Jan; 280(2):1482-9. PubMed ID: 15516335
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Neutralization of plasminogen activator inhibitor-1 inhibitory properties: identification of two different mechanisms.
    Debrock S; Declerck PJ
    Biochim Biophys Acta; 1997 Feb; 1337(2):257-66. PubMed ID: 9048903
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Identification of a functional epitope in plasminogen activator inhibitor-1, not localized in the reactive center loop.
    Debrock S; Declerck PJ
    Thromb Haemost; 1998 Mar; 79(3):597-601. PubMed ID: 9531048
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Epitopes on plasminogen activator inhibitor type-1 important for binding to tissue plasminogen activator.
    Björquist P; Ehnebom J; Inghardt T; Deinum J
    Biochim Biophys Acta; 1997 Aug; 1341(1):87-98. PubMed ID: 9300812
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Plasminogen activator inhibitor 1 contains a cryptic high affinity receptor binding site that is exposed upon complex formation with tissue-type plasminogen activator.
    Horn IR; van den Berg BM; Moestrup SK; Pannekoek H; van Zonneveld AJ
    Thromb Haemost; 1998 Nov; 80(5):822-8. PubMed ID: 9843178
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Immunological detection of conformational neoepitopes associated with the serpin activity of plasminogen activator inhibitor type-2.
    Saunders DN; Buttigieg KM; Gould A; McPhun V; Baker MS
    J Biol Chem; 1998 May; 273(18):10965-71. PubMed ID: 9556575
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Localization of epitopes for monoclonal antibodies to urokinase-type plasminogen activator: relationship between epitope localization and effects of antibodies on molecular interactions of the enzyme.
    Petersen HH; Hansen M; Schousboe SL; Andreasen PA
    Eur J Biochem; 2001 Aug; 268(16):4430-9. PubMed ID: 11502203
    [TBL] [Abstract][Full Text] [Related]  

  • 11. High-density mutagenesis by combined DNA shuffling and phage display to assign essential amino acid residues in protein-protein interactions: application to study structure-function of plasminogen activation inhibitor 1 (PAI-I).
    Stoop AA; Jespers L; Lasters I; Eldering E; Pannekoek H
    J Mol Biol; 2000 Sep; 301(5):1135-47. PubMed ID: 10966811
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Characterization of common neoantigenic epitopes generated in plasminogen activator inhibitor-1 after cleavage of the reactive center loop or after complex formation with various serine proteinases.
    Debrock S; Declerck PJ
    FEBS Lett; 1995 Dec; 376(3):243-6. PubMed ID: 7498551
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Identification of the binding site for a low-molecular-weight inhibitor of plasminogen activator inhibitor type 1 by site-directed mutagenesis.
    Björquist P; Ehnebom J; Inghardt T; Hansson L; Lindberg M; Linschoten M; Strömqvist M; Deinum J
    Biochemistry; 1998 Feb; 37(5):1227-34. PubMed ID: 9477948
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Importance of the hinge region between alpha-helix F and the main part of serpins, based upon identification of the epitope of plasminogen activator inhibitor type 1 neutralizing antibodies.
    Bijnens AP; Gils A; Knockaert I; Stassen JM; Declerck PJ
    J Biol Chem; 2000 Mar; 275(9):6375-80. PubMed ID: 10692438
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Elucidation of a novel epitope of a substrate-inducing monoclonal antibody against the serpin PAI-1.
    Naessens D; Gils A; Compernolle G; Declerck PJ
    J Thromb Haemost; 2003 May; 1(5):1028-33. PubMed ID: 12871373
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Vitronectin and substitution of a beta-strand 5A lysine residue potentiate activity-neutralization of PA inhibitor-1 by monoclonal antibodies against alpha-helix F.
    Schousboe SL; Egelund R; Kirkegaard T; Preissner KT; Rodenburg KW; Andreasen PA
    Thromb Haemost; 2000 May; 83(5):742-51. PubMed ID: 10823273
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Interaction of plasminogen activator inhibitor type-1 (PAI-1) with vitronectin.
    Arroyo De Prada N; Schroeck F; Sinner EK; Muehlenweg B; Twellmeyer J; Sperl S; Wilhelm OG; Schmitt M; Magdolen V
    Eur J Biochem; 2002 Jan; 269(1):184-92. PubMed ID: 11784312
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Importance of N-terminal residues in plasminogen activator inhibitor 1 on its antibody induced latency transition.
    Ngo TH; Zhou Y; Stassen JM; Declerck PJ
    Thromb Haemost; 2002 Aug; 88(2):288-93. PubMed ID: 12195702
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Determination of the vitronectin binding site on plasminogen activator inhibitor 1 (PAI-1).
    van Meijer M; Gebbink RK; Preissner KT; Pannekoek H
    FEBS Lett; 1994 Oct; 352(3):342-6. PubMed ID: 7523190
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Characterization of a panel of monoclonal antibodies toward mouse PAI-1 that exert a significant profibrinolytic effect in vivo.
    Van De Craen B; Scroyen I; Abdelnabi R; Brouwers E; Lijnen HR; Declerck PJ; Gils A
    Thromb Res; 2011 Jul; 128(1):68-76. PubMed ID: 21392818
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.